About Zymes Bioscience
Zymes Bioscience is a Healthcare company based in Delhi (India) founded in 2012 by Ashok Kumar Papneja, Mohit Bhatia, and Chandan Chopra. It develops innovative antibiotic therapies for medical treatment and bacterial resistance. It operates on a B2B model. The company has 51 employees. Its Indian entity Zymes Bioscience Private Limited reported revenue of ₹49.64 Cr. Zymes Bioscience offers products and services including Antibiotic Therapies and Innovative Products Pipeline. Its focus areas include Health Tech, Medical Innovations, Infectious Disease Solutions and Bacterial Resistance Management.
Company details
Zymes Bioscience focuses on creating innovative therapies for acute and life-threatening conditions, particularly in antibiotic treatment to address bacterial resistance. The company supports the medical community through product development and pipeline innovations. Based in New Delhi, it emphasizes team growth, customer input, and reliable solutions. They aim to deliver effective medical treatments while fostering collaboration and career opportunities within a dedicated team.
- Headquarters Delhi, India
- Employees 51
- Founders Ashok Kumar Papneja, Mohit Bhatia, Chandan Chopra
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website zymesbioscience.net
- Legal Name Zymes Bioscience Private Limited
- Date of Incorporation 09 Apr, 2012
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹49.64 Cr
FY 2025 · +23% YoY
- Net Profit₹1.62 Cr
FY 2025 · 3% margin
- EBITDA₹2.44 Cr
FY 2025 · 5% margin
- Employee Count51
Associated legal entities of Zymes Bioscience
Zymes Bioscience operates through Zymes Bioscience Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Zymes Bioscience Private Limited CIN U51102DL2012PTC234105 | Active | 09 Apr 2012 | New Delhi, Delhi | ₹49.6 Cr | 51 | 2 | View details |
Products & Services of Zymes Bioscience
Zymes Bioscience offers a comprehensive portfolio of products and services, including Antibiotic Therapies and Innovative Products Pipeline.
Therapies designed to treat acute illnesses and combat bacterial resistance effectively.
Upcoming solutions for overcoming bacterial resistance in medical applications.
Board of directors of Zymes Bioscience Private Limited (Zymes Bioscience)
Zymes Bioscience Private Limited is the primary company behind Zymes Bioscience. The board of Zymes Bioscience Private Limited currently have 2 directors; the longest-serving is Shivali Choudhary, appointed in 2022. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shivali Choudhary DIN 08125556 | Director | 25 May 2022 | 4 yrs 5 mo | Zymes Bioscience Private Limited |
| Chandan Chopra DIN 02289803 | Director | 01 May 2024 | 2 yrs 6 mo | Zymes Bioscience Private Limited |
People of Zymes Bioscience
3 people are tracked at Zymes Bioscience (3 in leadership); the tracked headcount is 51.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Co-Founder | Leadership | |
| Co-Founder | Leadership |
Complete people profiles for Zymes Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Zymes Bioscience
Figures of Zymes Bioscience Private Limited, the primary company behind Zymes Bioscience, for FY 2025. Revenue was ₹49.64 Cr (+23% year on year). Net profit was ₹1.62 Cr (3% margin). EBITDA was ₹2.44 Cr (5% margin). Revenue has grown at a compounded annual rate of +18% over three years and +84% over five years.
- ₹49.64 CrRevenue · FY 2025 · +23% YoY
- ₹1.62 CrNet profit · 3% margin
- ₹2.44 CrEBITDA · 5% margin
- ₹1 LakhPaid-up capital
- 51Employees (provident fund records)
- +18%Revenue CAGR, 3 years
- +84%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Zymes Bioscience Private Limited are on its company page.
Detailed financial statements for Zymes Bioscience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Zymes Bioscience
Zymes Bioscience was founded in 2012.
Zymes Bioscience is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Zymes Bioscience has 51 employees.
The primary company behind Zymes Bioscience, Zymes Bioscience Private Limited, reported revenue of ₹49.64 Cr for FY 2025, up 23% year on year.
Zymes Bioscience focuses on creating innovative therapies for acute and life-threatening conditions, particularly in antibiotic treatment to address bacterial resistance. The company supports the medical community through product development and pipeline innovations. Based in New Delhi, it emphasizes team growth, customer input, and reliable solutions. They aim to deliver effective medical treatments while fostering collaboration and career opportunities within a dedicated team.
Zymes Bioscience offers Antibiotic Therapies and Innovative Products Pipeline.
Zymes Bioscience operates through Zymes Bioscience Private Limited.
The legal entities of Zymes Bioscience currently have 2 directors, including Shivali Choudhary, Chandan Chopra.